No abstract

2012.01.01~2014.12.31 were identified and followed for 12 months after drug usage. Ttest, Chi-square test, binomial regression and generalized linear model adjusting for baseline demographics, cardiovascular events, inpatient days, and healthcare resource consumption were used to test the difference between two groups. RESULTS: A total of 439 patients were identified as using salvianolate injection (treatment group) and 1848 patients as control group (CHD or angina pectoris patients not using salvianolate injection), with mean (SD) age 75.4 (12.1) and 69.2 (12.8) (p<0.001) and male 43.3% and 52.4% (p<0.001), respectively. During the one-year baseline, the mean frequency of cardiovascular events were 2.1 and 5.8 times for treatment and control group respectively (p<0.001); the treatment cost for cardiovascular event were 4720.0 Chinese Yuan (CNY) and 3700.2 CNY for treatment and control group respectively (p¼0.11). During the follow-up period, after adjusting for baseline covariates, the average number of cardiovascular events were 0.3 and 5.9 times for treatment and control group respectively(p<0.001). Compared with non user, mean per-year cost for salvianolate injection user was 29.6% lower (4069.2 vs 5778.2 CNY). Compared with non user, mean per-year outpatient cost for salvianolate injection user was 74.2 vs 7400.1 CNY for non-user (p<0.001); while mean per-year inpatient cost for salvianolate injection user was 2858.8 vs 1468.3 CNY for non-user (p¼0.593). CONCLUSIONS: Among Chinese coronary heart disease or angina pectoris patients, those who used salvianolate injection had lower per-year cardiovascular event rate and spent less.OBJECTIVES: Gold standard treatment for stroke prevention in atrial fibrillation in Spain are vitamin K antagonists (VKA), such as warfarin. They are a low-priced choice, but have shown an important risk of bleeding. In the last years, direct oral anticoagulants (DOAC), like dabigatran, have appeared as an alternative treatment. Although DOAC are more expensive than VKA, real world data (RWD) shows similar or better efficacy and safety profile to warfarin. The aim of this study was to assess the potential cost-savings of dabigatran comparing to warfarin for the Spanish National Health Service (NHS), due to bleeding events reduction. METHODS: A network meta-analysis of 11 non-Asian RWD studies (2016)(2017) was performed to estimate the absolute and incremental bleeding events due to warfarin and dabigatran, and related costs. Both doses of dabigatran (110 mg and 150 mg) were included. The costs of bleeding events were taken from Diagnostic Related Groups (2015): 5.562V for intracranial bleeding, 4.107V for major and any bleeding, and updated to 2017 using the inflation rate. A weighted regression method with multiple hypothesis testing was used. RESULTS: The average percentage for all treatments of any bleeding was 5,34%, major bleeding 3,88% and intracranial bleeding 0,56%. The analysis shows that dabigatran reduces any bleeding by 1,18 percentage point (pp), major bleeding by 0,86pp ...